RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ligand Pharmaceuticals Stock

Ligand Pharmaceuticals Liabilities 2024

Ligand Pharmaceuticals Liabilities

86.3 M USD

Ticker

LGND

ISIN

US53220K5048

WKN

A1C9RN

In 2024, Ligand Pharmaceuticals's total liabilities amounted to 86.3 M USD, a -47.76% difference from the 165.2 M USD total liabilities in the previous year.

Ligand Pharmaceuticals Aktienanalyse

What does Ligand Pharmaceuticals do?

Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record. The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization. Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases. One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials. Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor. In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing. Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio. Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia. Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ligand Pharmaceuticals's Liabilities

Ligand Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ligand Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ligand Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ligand Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ligand Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ligand Pharmaceuticals stock

What is the level of liabilities of Ligand Pharmaceuticals this year?

Ligand Pharmaceuticals has a debt balance of 86.3 M USD this year.

What were the liabilities of Ligand Pharmaceuticals compared to the previous year?

The liabilities of Ligand Pharmaceuticals have increased by -47.76% dropped compared to the previous year.

What are the consequences of high debt for investors of Ligand Pharmaceuticals?

High liabilities can pose a risk for investors of Ligand Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ligand Pharmaceuticals?

Low liabilities mean that Ligand Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ligand Pharmaceuticals affect the company?

An increase in liabilities of Ligand Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ligand Pharmaceuticals affect the company?

A decrease in the liabilities of Ligand Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ligand Pharmaceuticals?

Some factors that can influence the liabilities of Ligand Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ligand Pharmaceuticals so important for investors?

The liabilities of Ligand Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ligand Pharmaceuticals take to modify the liabilities?

To change its liabilities, Ligand Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ligand Pharmaceuticals pay?

Over the past 12 months, Ligand Pharmaceuticals paid a dividend of 15 USD . This corresponds to a dividend yield of about 12.44 %. For the coming 12 months, Ligand Pharmaceuticals is expected to pay a dividend of 5.37 USD.

What is the dividend yield of Ligand Pharmaceuticals?

The current dividend yield of Ligand Pharmaceuticals is 12.44 %.

When does Ligand Pharmaceuticals pay dividends?

Ligand Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ligand Pharmaceuticals?

Ligand Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ligand Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 5.37 USD are expected. This corresponds to a dividend yield of 4.45 %.

In which sector is Ligand Pharmaceuticals located?

Ligand Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ligand Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ligand Pharmaceuticals from 4/19/2007 amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on 4/3/2007.

When did Ligand Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2007.

What was the dividend of Ligand Pharmaceuticals in the year 2023?

In the year 2023, Ligand Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ligand Pharmaceuticals pay out the dividend?

The dividends of Ligand Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ligand Pharmaceuticals

Our stock analysis for Ligand Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ligand Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.